Engitix and GSK Partner to Advance New Targets for Liver Fibrosis Treatment
Tuesday, June 09, 2026
Engitix has entered into a strategic research collaboration and option agreement with GSK to identify and validate novel therapeutic targets aimed at promoting liver fibrosis regression.
The partnership combines Engitix’s proprietary human extracellular matrix (ECM) platform and multi-omics datasets with GSK’s drug development expertise. The collaboration will focus on understanding the biological mechanisms that drive the reversal of liver fibrosis, an area that remains largely unexplored in drug discovery.
Through the agreement, Engitix will use its human ECM-based disease models and generate high-resolution translational multi-omics data to identify new targets linked to fibrosis resolution in liver disease. GSK will have the option to license the resulting assays, datasets and therapeutic targets. The company will also lead any subsequent research, development and commercialisation activities related to targets emerging from the collaboration.
Under the terms of the deal, Engitix could receive up to £44.5 million in upfront and near-term payments. The company is also eligible for up to £118 million per target in milestone payments, along with tiered low single-digit royalties on future product sales.
The collaboration highlights Engitix’s ECM platform as a tool for studying fibrosis regression in human tissue and is expected to support the discovery of high-confidence therapeutic targets based on human disease biology. By combining Engitix’s disease models with GSK’s development capabilities, the companies aim to accelerate the development of new treatments for liver fibrosis.
GSK said the partnership will provide access to Engitix’s human biology platform and complement its existing capabilities in fibrosis research, supporting efforts to develop differentiated therapies for patients with fibrotic liver diseases.
Source: globenewswire.com
